IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Furthering cell therapy ambition across oncology and autoimmune diseases
Development services for gene and cell therapies is planned to begin first in 2025
Subscribe To Our Newsletter & Stay Updated
